| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a3980937591b8ff05d11e5056982422 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-6615
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-6615
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2013-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f58a6a4b72c51e33a651caac6a6f01d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ce387de654fe98473d62235d177dd3d |
| publicationDate |
2014-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014060347-A1 |
| titleOfInvention |
Fosfestrol for use in curative or palliative treatment of prostate cancer |
| abstract |
The present invention relates to the use of Fosfestrol (diethylstilbestrol diphosphate) in a method of curative or palliative treatment of prostate cancer in male mammals, said method comprising orally administering Fosfestrol in a daily dosage of at least 1,000 mg. The inventors have discovered that Fosfestrol when administered in very high oral dosages is effective in the treatment of prostate cancer, especially hormone resistant prostate cancer, without giving rise to serious side effects, such as thromboembolic toxicity or mortality. The invention further provides an oral dosage unit comprising at least 500 mg, of Fosfestrol. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2589266-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10722527-B2 |
| priorityDate |
2012-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |